Omar Alhalabi, MD, Amishi Y. Shah, MD, Emily A. Lemke, DNP, AGPCNP-BC, AOCNP, and Jianjun Gao, MD, PhD
In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Kristina Frinzi Byers, PharmD, BCOP
An oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: UBM Medica, a divsion of UBM Americas
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
Omar Alhalabi, MD, Amishi Y. Shah, MD, Emily A. Lemke, DNP, AGPCNP-BC, AOCNP, and Jianjun Gao, MD, PhD
Kristina Frinzi Byers, PharmD, BCOP
